selegiline ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
monoamine oxydase (MAO)-inhibitors type B 2429 14611-51-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • selegiline
  • (-)-deprenil
  • (-)-deprenyl
  • (-)-selegiline
  • (r)-(-)-deprenyl
  • (r)-selegiline
  • anipryl
  • l-deprenyl
  • selegina
  • selgene
  • zelapar
  • selegiline hydrochloride
  • selegiline HCl
A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.
  • Molecular weight: 187.29
  • Formula: C13H17N
  • CLOGP: 2.84
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 0
  • TPSA: 3.24
  • ALOGS: -3.87
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.89 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 4.40 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.13 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 5, 1989 FDA SOMERSET

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Application site rash 180.02 28.77 35 1600 2322 50601167
Application site erythema 168.21 28.77 37 1598 4501 50598988
Application site pruritus 97.89 28.77 23 1612 3736 50599753
Application site reaction 83.12 28.77 15 1620 659 50602830
Dyskinesia 79.89 28.77 31 1604 27830 50575659
Application site urticaria 75.13 28.77 12 1623 250 50603239
Hallucination 73.78 28.77 34 1601 46623 50556866
Hallucination, visual 67.96 28.77 24 1611 16558 50586931
Parkinsonism hyperpyrexia syndrome 67.34 28.77 10 1625 126 50603363
Application site irritation 58.84 28.77 13 1622 1602 50601887
Drug interaction 36.15 28.77 38 1597 199583 50403906
Application site pain 29.80 28.77 9 1626 3789 50599700

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 154.61 30.44 74 2299 44638 29527516
Dyskinesia 123.91 30.44 50 2323 20011 29552143
Hypersexuality 84.47 30.44 20 2353 1336 29570818
Hallucination, visual 84.36 30.44 35 2338 14980 29557174
Impulse-control disorder 81.20 30.44 19 2354 1206 29570948
Gambling disorder 76.45 30.44 19 2354 1556 29570598
Dopamine dysregulation syndrome 73.90 30.44 14 2359 315 29571839
On and off phenomenon 67.84 30.44 18 2355 1910 29570244
Application site rash 67.61 30.44 15 2358 749 29571405
Delusion 62.49 30.44 26 2347 11190 29560964
Application site erythema 43.70 30.44 13 2360 2086 29570068
Parkinsonism hyperpyrexia syndrome 41.31 30.44 7 2366 81 29572073
Impulsive behaviour 31.79 30.44 10 2363 1933 29570221

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 171.98 27.23 81 3266 72707 64422678
Application site rash 163.99 27.23 34 3313 1920 64493465
Dyskinesia 159.04 27.23 64 3283 39324 64456061
Hallucination, visual 147.06 27.23 55 3292 27779 64467606
Application site erythema 129.43 27.23 33 3314 4656 64490729
Parkinsonism hyperpyrexia syndrome 106.50 27.23 17 3330 213 64495172
Impulse-control disorder 95.50 27.23 21 3326 1567 64493818
Gambling disorder 86.47 27.23 20 3327 1874 64493511
Hypersexuality 85.85 27.23 19 3328 1460 64493925
Dopamine dysregulation syndrome 74.73 27.23 14 3333 465 64494920
Delusion 71.66 27.23 29 3318 17985 64477400
Application site pruritus 60.20 27.23 17 3330 3522 64491863
Application site urticaria 50.20 27.23 9 3338 233 64495152
Application site irritation 43.02 27.23 11 3336 1565 64493820
On and off phenomenon 42.39 27.23 12 3335 2507 64492878
Muscle rigidity 36.74 27.23 18 3329 17455 64477930
Orthostatic hypotension 35.82 27.23 25 3322 46713 64448672
Insomnia 31.95 27.23 45 3302 197791 64297594
Sudden onset of sleep 30.91 27.23 7 3340 596 64494789
Psychotic disorder 30.07 27.23 20 3327 34558 64460827
Drug interaction 29.89 27.23 61 3286 362022 64133363
Application site reaction 29.72 27.23 7 3340 708 64494677
Sleep talking 27.29 27.23 7 3340 1008 64494377

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N04BD01 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Monoamine oxidase B inhibitors
FDA MoA N0000000184 Monoamine Oxidase Inhibitors
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000928 Antidepressive Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D008996 Monoamine Oxidase Inhibitors
MeSH PA D018696 Neuroprotective Agents
MeSH PA D020011 Protective Agents
MeSH PA D011619 Psychotropic Drugs
CHEBI has role CHEBI:176497 geroprotectors
CHEBI has role CHEBI:38623 monoamine oxidase inhibitors
CHEBI has role CHEBI:48407 antiparkinson agent
CHEBI has role CHEBI:48560 dopaminergic agents
FDA EPC N0000175744 Monoamine Oxidase Inhibitor
FDA MoA N0000175761 Monoamine Oxidase-B Inhibitors
FDA EPC N0000175762 Monoamine Oxidase Type B Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Parkinson's disease indication 49049000 DOID:14330
Major depressive disorder indication 370143000
Suicidal thoughts contraindication 6471006
Bipolar disorder contraindication 13746004 DOID:3312
Orthostatic hypotension contraindication 28651003
Conduction disorder of the heart contraindication 44808001
Psychotic disorder contraindication 69322001
Kidney disease contraindication 90708001 DOID:557
Tardive dyskinesia contraindication 102449007
Angina pectoris contraindication 194828000
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Pheochromocytoma contraindication 302835009
Malignant melanoma contraindication 372244006




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Cognitive dysfunction syndrome (CDS) Indication
Dogs Pituitary dependent hyperadrenocorticism (PDH) Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Anipryl Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.6 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Amine oxidase [flavin-containing] B Enzyme INHIBITOR Ki 7.26 CHEMBL CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 6.76 DRUG MATRIX
Amine oxidase [flavin-containing] A Enzyme Ki 5.04 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.17 DRUG MATRIX
Alpha-synuclein Transporter IC50 6.57 CHEMBL
Amine oxidase [flavin-containing] B Enzyme Ki 5.87 CHEMBL
Amine oxidase [flavin-containing] A Enzyme Ki 4.98 CHEMBL
Amine oxidase [flavin-containing] A Enzyme Ki 5.42 CHEMBL
Amine oxidase [flavin-containing] B Enzyme Ki 6.01 CHEMBL
Monoamine oxidase Enzyme IC50 7.89 CHEMBL

External reference:

IDSource
4019929 VUID
N0000148014 NUI
D00785 KEGG_DRUG
14611-52-0 SECONDARY_CAS_RN
4019485 VANDF
4019929 VANDF
C0036579 UMLSCUI
CHEBI:50217 CHEBI
CHEMBL972 ChEMBL_ID
DB01037 DRUGBANK_ID
CHEMBL1200904 ChEMBL_ID
D012642 MESH_DESCRIPTOR_UI
26757 PUBCHEM_CID
4436 INN_ID
6639 IUPHAR_LIGAND_ID
2K1V7GP655 UNII
203137 RXNORM
1551 MMSL
21238 MMSL
53269 MMSL
5448 MMSL
63129 MMSL
d00976 MMSL
003465 NDDF
004599 NDDF
108466000 SNOMEDCT_US
108467009 SNOMEDCT_US
372497003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZELAPAR HUMAN PRESCRIPTION DRUG LABEL 1 0187-0453 TABLET, ORALLY DISINTEGRATING 1.25 mg ORAL NDA 25 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-737 CAPSULE 5 mg ORAL ANDA 20 sections
Selegiline Hydrochloride Human Prescription Drug Label 1 16571-659 CAPSULE 5 mg ORAL ANDA 19 sections
EMSAM HUMAN PRESCRIPTION DRUG LABEL 1 49502-900 PATCH 6 mg TRANSDERMAL NDA 31 sections
EMSAM HUMAN PRESCRIPTION DRUG LABEL 1 49502-901 PATCH 9 mg TRANSDERMAL NDA 31 sections
EMSAM HUMAN PRESCRIPTION DRUG LABEL 1 49502-902 PATCH 12 mg TRANSDERMAL NDA 31 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-2918 TABLET 5 mg ORAL ANDA 19 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60429-176 TABLET 5 mg ORAL ANDA 20 sections
SELEGILINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 60505-0055 CAPSULE 5 mg ORAL ANDA 13 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60505-3438 TABLET 5 mg ORAL ANDA 20 sections
SELEGILINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 68151-2649 CAPSULE 5 mg ORAL ANDA 19 sections
Selegiline Hydrochloride Human Prescription Drug Label 1 70954-504 CAPSULE 5 mg ORAL ANDA 20 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71205-888 CAPSULE 5 mg ORAL ANDA 19 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71205-888 CAPSULE 5 mg ORAL ANDA 19 sections
Selegiline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 72319-006 TABLET 5 mg ORAL ANDA 15 sections